Trial Profile
A Open-label, Multicenter Study, With a Single Intravenous Dose of QAX576 to Determine IL-13 Production in Patients With Idiopathic Pulmonary Fibrosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dectrekumab (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Pharmacodynamics
- Sponsors Novartis Pharmaceuticals; Novartis Pharmaceuticals Corporation
- 27 Jun 2014 New trial record